Penetrance estimates for BRCA1, BRCA2 (also applied to Lynch syndrome) based on presymptomatic testing: a new unbiased method to assess risk?
dc.contributor.author | Evans, D | |
dc.contributor.author | Woodward, E | |
dc.contributor.author | Harkness, E | |
dc.contributor.author | Howell, Anthony | |
dc.contributor.author | Plaskocinska, I | |
dc.contributor.author | Maher, E | |
dc.contributor.author | Tischkowitz, M | |
dc.contributor.author | Lalloo, F | |
dc.date.accessioned | 2018-04-28T20:50:37Z | |
dc.date.available | 2018-04-28T20:50:37Z | |
dc.date.issued | 2018-02-26 | |
dc.identifier.citation | Penetrance estimates for BRCA1, BRCA2 (also applied to Lynch syndrome) based on presymptomatic testing: a new unbiased method to assess risk? 2018, J Med Genet | en |
dc.identifier.issn | 1468-6244 | |
dc.identifier.pmid | 29483236 | |
dc.identifier.doi | 10.1136/jmedgenet-2017-105223 | |
dc.identifier.uri | http://hdl.handle.net/10541/620916 | |
dc.description.abstract | The identification of BRCA1, BRCA2 or mismatch repair (MMR) pathogenic gene variants in familial breast/ovarian/colorectal cancer families facilitates predictive genetic testing of at-risk relatives. However, controversy still exists regarding overall lifetime risks of cancer in individuals testing positive. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Journal of medical genetics | en |
dc.title | Penetrance estimates for BRCA1, BRCA2 (also applied to Lynch syndrome) based on presymptomatic testing: a new unbiased method to assess risk? | en |
dc.type | Article | en |
dc.contributor.department | Division of Evolution and Genomic Science, Manchester Centre for Genomic Medicine, Manchester Academic Health Science Centre, University of Manchester, Manchester, UKManchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK | en |
dc.identifier.journal | Journal of Medical Genetics | en |
html.description.abstract | The identification of BRCA1, BRCA2 or mismatch repair (MMR) pathogenic gene variants in familial breast/ovarian/colorectal cancer families facilitates predictive genetic testing of at-risk relatives. However, controversy still exists regarding overall lifetime risks of cancer in individuals testing positive. |